Clinical Trial Search

Primary: Recommended Phase 2 Dose for Enzastaurin Plus Erlotinib Combination Therapy (Assess the Tolerated Dose of the Combination Erlotinib and Enzastaurin) — 500; 150…

Primary: Progression-Free Survival (PFS) — 3.5; 4.3 months — p=0.469

Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs): Injection Phase — 47; 1 Participants

Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)…

Primary: Change From Baseline in the Numerical Rating Score (NRS) for Pruritus (Worst Itch) — 7.3; 7.26; 4.27; 4.6 score on a scale — p== 0.249

Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points — 10.0; 10.0; 12.0 days — p=0.9561

Primary: Maximum Tolerated Dose (MTD) (Phase 1) — 25 micrograms

Primary: Change in Hamilton Rating Scale for Depression (HRSD) Score, Minus the Sleep Item — -7.62; -5.92; -8.21; -6.18 change in score — p=.367

Primary: Insulin Sensitivity at 6 Months From Baseline — 9.9; 6.4 (mL/kg/min)/(microIU/mL) — p=<0.05

Primary: Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline — 49; 58 Participants — p=0.35

Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment (SVR-12) — 7 Participants

Primary: Progression-free Survival — 2.1; NA years — p=0.015

Primary: Survival Without BPD at 36 Weeks Post Menstrual Age. — 79; 82 Participants — p=0.89

Primary: Mean Change From Baseline in Best Corrected Visual Acuity Letter Score — 11.4; 13.8 letters — p=0.288

Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 6.4; 5.9; -2.3; -1.1 units on a scale